These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 21401726

  • 1. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
    Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, Mateczun AJ, Cross AS, Baillie LW.
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
    [Abstract] [Full Text] [Related]

  • 2. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
    Dumas EK, Demiraslan H, Ingram RJ, Sparks RM, Muns E, Zamora A, Larabee J, Garman L, Ballard JD, Boons GJ, James JA, Kayabas U, Doganay M, Farris AD.
    PLoS One; 2020 Jul; 15(4):e0230782. PubMed ID: 32294093
    [Abstract] [Full Text] [Related]

  • 3. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK, Gross T, Larabee J, Pate L, Cuthbertson H, Charlton S, Hallis B, Engler RJM, Collins LC, Spooner CE, Chen H, Ballard J, James JA, Farris AD.
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [Abstract] [Full Text] [Related]

  • 4. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Westra H, Galloway D, Mateczun A, Goldman S, Groen H, Baillie LW.
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [Abstract] [Full Text] [Related]

  • 5. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
    Taft SC, Weiss AA.
    Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of toxin functional domains in anthrax pathogenesis.
    Brossier F, Weber-Levy M, Mock M, Sirard JC.
    Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of the human immune response to the UK anthrax vaccine.
    Baillie L, Townend T, Walker N, Eriksson U, Williamson D.
    FEMS Immunol Med Microbiol; 2004 Oct 01; 42(2):267-70. PubMed ID: 15364114
    [Abstract] [Full Text] [Related]

  • 18. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
    Glinert I, Bar-David E, Sittner A, Weiss S, Schlomovitz J, Ben-Shmuel A, Mechaly A, Altboum Z, Kobiler D, Levy H.
    Antimicrob Agents Chemother; 2016 Aug 01; 60(8):4878-85. PubMed ID: 27270276
    [Abstract] [Full Text] [Related]

  • 19. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
    Vrentas CE, Moayeri M, Keefer AB, Greaney AJ, Tremblay J, O'Mard D, Leppla SH, Shoemaker CB.
    J Biol Chem; 2016 Oct 07; 291(41):21596-21606. PubMed ID: 27539858
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS, Lee JH, Hung CF, Wu TC, Kim TW.
    Infect Immun; 2008 May 07; 76(5):1952-9. PubMed ID: 18285494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.